DIANA Biotechnologies turns into a joint stock company

DIANA Biotechnologies, a Czech biotechnology company, has announced the successful completion of a merger and change of its legal form from a limited liability company (s.r.o.) to a joint stock company (a.s.) as of 13 September 2023. DIANA Lab, s.r.o. and DIANA Engineering, s.r.o., whose activities were taken over by the newly established DIANA Biotechnologies, a.s., were dissolved.

Founded in 2018, DIANA Biotechnologies became a major player in PCR diagnostics during the Covid-19 pandemic. During the epidemic, the company developed and launched automated PCR testing systems, which helped save thousands of lives in the Czech Republic. With annual growth of 335% in 2021 and revenues of €38.7 million, the firm was ranked number one in the Deloitte CE Fast 50 Companies in 2022.

Merger and transformation move for international expansion

By eliminating the need for DNA extraction, the protocol significantly reduces preparation time, allowing researchers to process samples more quickly. In addition to its success in covid-19 PCR testing, the company is investing its profits in research and development in the areas of molecular diagnostics, drug discovery services and monoclonal antibody development. With more than 100 employees and revenues in excess of €60 million, DIANA Biotechnologies plans to expand beyond the Czech Republic and Europe. The company is focused on attracting top talent in chemistry, biology and IT and expanding its research and commercial collaborations.

The project of transformation into a joint stock company entails significant changes in the form of the dissolution of the sister companies DIANA Lab, s.r.o. and DIANA Engineering, s.r.o., which become part of DIANA Biotechnologies, a.s. The merger and transformation is another step towards international expansion, which will be a primary goal for the company in the coming years. As a result of the conversion and merger, the company's headquarters have been moved to Průmyslová 596, 252 50 Vestec. All business relations, rights and obligations will be transferred to DIANA Biotechnologies without any changes for partners and customers. Correspondence addresses and contact details remain unchanged.

Media contact:

Petr Kašík

E-mail: [email protected]

Tel: +420734513384

About DIANA Biotechnologies

DIANA Biotechnologies, a.s. is a Czech biotechnology company with strong in-house research and development. The company was founded in 2018 with the aim to develop applications of the patented DIANA technology in diagnostics and drug development. However, the company's portfolio is now significantly broader. It is currently targeting global markets in three main areas: 1) development and production of PCR products for diagnostics and life science, 2) development of proprietary original low molecular weight drugs and provision of services to the pharmaceutical sector, and 3) development of antibodies for diagnostics and therapeutics. In the field of molecular diagnostics, the company has become the largest Czech manufacturer of PCR tests for COVID-19 and other viral diseases and is now making its mark abroad thanks to its innovations in PCR diagnostics. The company is built on a team of top scientists with unique expertise in molecular biology, biochemistry, organic and medicinal chemistry, pharmacology and laboratory automation. DIANA Biotechnologies aims to become a multinational biotechnology company developing its own original diagnostics and pharmaceuticals. For more information about the company, please continue to www.dianabiotech.com